IESE (España)
-
A New Model for the Pharmaceutical Industry: The Institute of OneWorld Health
Schoen, Oliver; Mair, JohannaCase DG-1480-EEntrepreneurship, Innovation and ChangeThis case introduces the Institute of OneWorld Health, a company dedicated to producing drugs for neglected diseases and the first non-profit pharmaceutical company in the world. Founded in 2000 by Dr. Victoria Hale, IOWH took expired and donated patent compounds and developed them through all the stages of clinical testing and approval into drugs to fight the world's most destructive diseases, usually occurring in Third World countries where per...Starting at €8.20
-
Mango: Strategic Choices in a Disruptive Context
Raventós, Andrea; Canals, JordiCase SM-1736-ECorporate Governance, StrategyThis case describes Mango's evolution from the 1990s on, the crisis the Group went through from 2011 to 2015, the transformation it underwent to emerge from that crisis, and its new strategy for 2022-24. The geopolitical changes of recent years and technological transformation force the CEO and the board to reconsider whether the company's strategic directions are the right ones to pursue.Starting at €8.20
-
Merger of Three. The Integration of Allianz, AGF and Athena in Spain
Lupu, Raluca; Mair, JohannaCase DG-1404-EStrategyAt the end of 1997 Allianz, the German insurance group, acquired AGF, a key player in the French market. With this move Allianz not only reinforced its strategy of multilocality, but also added momentum to the ongoing consolidation process in the European and global insurance sector. In the course of the merger implementation process several issues appeared; among the most prominent, the integration of existing businesses (subsidiaries) in other ...Starting at €8.20
-
Mango: retos estratégicos en un entorno incierto
Raventós, Andrea; Canals, JordiCase SM-1736Corporate Governance, StrategyEste caso describe la evolución de Mango desde los años 1990, la crisis 2011-2015, la transformación para la salida de la crisis, y la nueva estrategia 2022-2024. Los cambios geopolíticos de los últimos años y la transformación tecnológica fuerzan al CEO y al Consejo a reconsiderar si las líneas estratégicas de la empresa son las adecuadas.Starting at €8.20